Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer Pc 4 for primary or metastatic cutaneous cancers

Frontiers in Oncology

Volumn 1, Issue JUN, 2011, Pages

  Kinsella, Timothy James ^a,b   Baron, Elma D ^a,b,c,d   Colussi, Valdir C ^a   Cooper, Kevin D ^a,b,c,d   Hoppel, Charles L ^b,c   Ingalls, Stephen T ^c   Kenney, Malcolm E ^b   Li, Xiaolin ^c   Oleinick, Nancy L ^b,c   Stevens, Seth R ^a,b,c,d   Remick, Scot C ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Cutaneous cancers; Pc 4; Photodynamic therapy; Phthalocyanine

Indexed keywords

EID: 84865995758     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00014     Document Type: Article

References (28)

1. Agarwal, R., Korman, N. J., Mohan, R. R., Feyes, D. K., Jawed, S., Zaim, M. T., and Mukhtar, H. (1996). Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin. Photochem. Photobiol. 63, 547-552.
2. Allison, R., Sibata, C., Mang, T. S., Bagnato, V. S., Downie, G. H., Hu, X. H., and Cuenca, R. (2004). Photodynamic therapy for chest wall recurrence from breast cancer. Photodiagnosis Photodyn. Ther. 1, 157-171.
3. Allison, R. R., Mang, T. S., Hewson, G., Snider, W., and Dougherty, T. J. (2001). Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer 91, 1-8.
4. Anderson, C., Hrabovsky, S., McKinley, Y., Tubesing, K., Tang, H.-P., Dunbar, R., Mukhtar, H., and Elmets, C. A. (1997). Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Photochem. Photobiol. 65, 895-901.
5. Anderson, C. Y., Freye, K., Tubesing, K. A., Li, Y.-S., Kenney, M. E., Mukhtar, H., and Elmets, C. A. (1998). A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice. Photochem. Photobiol. 67, 332-336.
6. Baron, E. D., Malbasa, C. L., Santo-Domingo, D., Fu, P., Miller, J. D., Hanneman, K. K., Hsia, A. H., Oleinick, N. L., Colussi, V. C., and Cooper, K. D. (2010). Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg. Med. 42, 728-735.
7. Brown, S. B., Brown, E. A., and Walker, I. (2004). The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5, 497-508.
8. Carraro, C., and Pathak, M. A. (1988). Studies on the nature of in vitro and in vivo photosensitization reactions by psoralens and porphyrins. J. Invest. Dermatol. 90, 267-275.
9. Colussi, V. C., Feyes, D. K., Mulvihill, J. W., Li, Y.-S., Kenney, M. E., Elmets, C. A., Oleinick, N. L., and Mukhtar, H. (1999). Phthalocyanine (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. Photobiol. 69, 236-241.
10. Cuenca, R. E., Allison, R. R., Sibata, C., and Downie, G. H. (2004). Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann. Surg. Oncol. 11, 322-327.
11. Dimofte, A., Zhu, T. C., Hahn, S. M., and Lustig, R. A. (2002). In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg. Med. 31, 305-312.
12. Dolmans, D. E. J. G. J., Fukumura, D., and Jain, R. K. (2003). Photodynamic therapy for cancer. Nat. Rev. Cancer 3, 380-387.
13. Egorin, M. J., Zuhowski, E. G., Sentz, D. L., Dobson, J. M., Callery, P. S., and Eiseman, J. L. (1999). Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc 4 (NSC 676418), a silicon phthalocyanine photodynamic sensitizing agent. Cancer Chemother. Pharmacol. 44, 283-294.
14. Huang, Z., Xu, H., Meyers, A. D., Musani, A. I., Wang, L., Tagg, R., Barqawi, A. B., and Chen, Y. K. (2008). Photodynamic therapy for treatment of solid tumors-potential and technical challenges. Technol. Cancer Res. Treat. 7, 309-320.
15. Ke, M. S., Xue, L. Y., Feyes, D. K., Azizuddin, K., Baron, E. D., McCormick, T. S., Mukhtar, H., Panneerselvam, A., Schluchter, M. D., Cooper, K. D., Oleinick, N. L., and Stevens, S. R. (2008). Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells versus A-431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem. Photobiol. 84, 407-414.
16. Lam, M., Lee, Y., Deng, M., Hsia, A. H., Morrissey, K. A., Yan, C., Azzizudin, K., Oleinick, N. L., McCormick, T. S., Cooper, K. D., and Baron, E. D. (2010). Photodynamic therapy with the silicon phthalocyanine Pc 4 induces apoptosis in mycosis fungoides and Sezary syndrome. Adv. Hematol. 2010, 896161.
17. Lam, M., Liu, Y., Hsia, A. H., Oleinick, N. L., Kenney, M. E., McCormick, T. D., Cooper, K. D., and Baron, E. D. (2011). Successful cutaneous delivery of the photosensitizer silicon phthalocyanine Pc 4 for photodynamic therapy. Clin. Exp. Dermatol. doi: 10.1111/j.1365-2230.2010.03989.x. [Epub ahead of print].
18. Mang, T. S., Allison, R., Hewson, G., Snider, W., and Moskowitz, R. (1998). A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J. 6, 378-384.
19. Miller, J. D., Baron, E. D., Scull, H., Hsia, A., Berlin, J. C., McCormick, T., Colussi, V., Kenney, M. E., Cooper, K. D., and Oleinick, N. L. (2007). Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol. Appl. Pharmacol. 224, 290-299.
20. Morton, C. A., McKenna, K. E., and Rhodes, L. E. (2008). Guidelines for topical photodynamic therapy: update. Br. J. Dermatol. 159, 1245-1266.
21. Ohtola, J., Sugiyama, H., Rodriguez, M. E., Oleinick, N. L., Lam, M., McCormick, T. S., Cooper, K. D., and Baron, E. D. (2010). Photodynamic therapy with the phthalocyanine Pc 4 for T cell mediated diseases: activated T cells exhibit increased uptake of Pc 4 and increased susceptibility to PDT-mediated cell death. J. Invest. Dermatol. 130, S129.
22. Oleinick, N. L., Antunez, A. R., Clay, M. E., Rihter, B. D., and Kenney, M. E. (1993). New phthalocyanine photosensitizers for photodynamic therapy. Photochem. Photobiol. 57, 242-247.
23. Oleinick, N. L., Morris, R. L., and Belichenko, I. (2002). Apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci. 1, 1-21.
24. Oseroff, A. R., Blumenson, L. R., Wilson, B. D., Mang, T. S., Bellnier, D. A., Parsons, J. C., Frawley, N., Cooper, M., Zeitouni, N., and Dougherty, T. J. (2006). A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg. Med. 38, 417-426.
25. Renschler, M. F., Yuen, A. R., Panella, T. J., Wieman, T. O., Dougherty, S., Esserman, L., Panjehpour, M., Taber, S. W., Fingar, V. M., Lowe, E., Engel, J. S., Lum, B., and Woodburn, K. (1998). Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer. Proc. SPIE 3247, 35-39.
26. Triesscheijn, M., Baas, P., Schellens, J. H. M., and Stewart, F. A. (2006). Photodynamic therapy in oncology. Oncologist 11, 1034-1044.
27. Wyss, P., Schwarz, V., Dobler-Girdziunaite, D., Hornung, R., Walt, H., Degen, A., and Fehr, M. K. (2001). Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int. J. Cancer 93, 720-724.
28. Zaidi, S. I. A., Oleinick, N. L., Zaim, M. T., and Mukhtar, H. (1993). Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic, and biochemical evidence. Photochem. Photobiol. 58, 771-776.